# Bevacizumab Against Recurrent Retinal Detachment

> **NCT02192970** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 101 (actual)

## Conditions studied

- Retinal Detachment
- Proliferative Vitreoretinopathy

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02192970
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-21
- **Primary completion:** 2019-11-11
- **Final completion:** 2019-11-11
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2021-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192970, "Bevacizumab Against Recurrent Retinal Detachment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02192970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*